Chimeric Therapeutics Limited

ASX:CHM Stock Report

Market Cap: AU$9.1m

Chimeric Therapeutics Balance Sheet Health

Financial Health criteria checks 5/6

Chimeric Therapeutics has a total shareholder equity of A$2.5M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$15.3M and A$12.8M respectively.

Key information

0%

Debt to equity ratio

AU$0

Debt

Interest coverage ration/a
CashAU$3.05m
EquityAU$2.47m
Total liabilitiesAU$12.80m
Total assetsAU$15.27m

Recent financial health updates

Recent updates

Here's Why We're Watching Chimeric Therapeutics' (ASX:CHM) Cash Burn Situation

Oct 13
Here's Why We're Watching Chimeric Therapeutics' (ASX:CHM) Cash Burn Situation

Here's Why We're Watching Chimeric Therapeutics' (ASX:CHM) Cash Burn Situation

Feb 23
Here's Why We're Watching Chimeric Therapeutics' (ASX:CHM) Cash Burn Situation

We Think Chimeric Therapeutics (ASX:CHM) Needs To Drive Business Growth Carefully

Oct 20
We Think Chimeric Therapeutics (ASX:CHM) Needs To Drive Business Growth Carefully

Financial Position Analysis

Short Term Liabilities: CHM's short term assets (A$3.2M) do not cover its short term liabilities (A$10.1M).

Long Term Liabilities: CHM's short term assets (A$3.2M) exceed its long term liabilities (A$2.7M).


Debt to Equity History and Analysis

Debt Level: CHM is debt free.

Reducing Debt: CHM had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CHM has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: CHM is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies